针对澳大利亚晚期皮肤状细胞癌的免疫检查点抑制剂疗法:一项回顾性的真实世界队列研究
Luke S McLean1,2, Annette M Lim1,2, Mathias Bressel2,3
1Peter MacCallum Cancer Centre, Melbourne, VIC.
The Medical journal of Australia
|January 11, 2024
概括
免疫检查点抑制剂 (ICI) 在不符合临床试验条件的晚期皮肤状细胞癌 (CSCC) 患者中显示出有效性和良好的耐受性. 这些现实结果反映了临床研究的结果,支持ICI在更广泛的患者群体中使用.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 皮肤病学 皮肤病学
背景情况:
- 晚期皮肤状细胞癌 (CSCC) 是一个重要的治疗挑战,特别是对于无法参加临床试验的患者来说.
- 免疫检查点抑制剂 (ICI) 已成为各种癌症的有希望的治疗选择.
研究的目的:
- 评估免疫检查点抑制剂 (ICI) 治疗晚期皮肤状细胞癌 (CSCC) 的现实结果,在不参与临床试验的患者中.
- 评估ICI在更广泛的CSCC患者群体中的有效性和安全性.
主要方法:
- 进行了一项回顾性观察性研究,分析了来自澳大利亚15个机构的患者记录.
- 收集了2017年5月至2022年5月期间用ICI治疗局部晚期或转移性CSCC的成年患者的数据.
- 结果包括使用RECIST 1.1的最佳整体应答率 (ORR),整体生存率和无进展生存率.
主要成果:
- 共有286名患者接受了ICI治疗 (西米普利马布或潘布罗利祖马布).
- 总体应答率 (ORR) 为60%,12个月总生存率为78%,无进展生存率为65%.
- 较差的ECOG表现状态和免疫功能受损与更差的生存结果有关. 2级或更高的免疫相关不良事件发生在19%的患者中,没有与治疗相关的死亡.
结论:
- 免疫检查点抑制剂 (ICI) 治疗在晚期CSCC患者中显示出与临床试验结果相比的有效性和毒性.
- 这些现实结果表明,ICI对于那些不符合临床试验资格标准的晚期CSCC患者来说是一种可行且耐受良好的治疗选择.
相关概念视频
Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
Skin Cancer
4.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.1K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


